Institutional Review Board (IRB) Mutual Recognition Program and Its Feasibility in Korea |
Cheong, Hye-Rim
(Office of Human Research Protection, Catholic Medical Center, The Catholic University of Korea)
Yim, Hyeon-Woo (Department of preventive medicine, College of Medicine, The Catholic University of Korea) Choe, Byung-In (Office of Human Research Protection, Catholic Medical Center, The Catholic University of Korea) Kim, Yeong-In (Department of Neurology, Seoul St. Mary's Hospital, The Catholic University of Korea) |
1 | Shin HY. Improving the Efficiency of IRB through Joint IRB in Multicenter Clinical Trials in Korea. Kor J Clin Pharmacol Ther, 2009;17(1):44-50. (Korean) |
2 | U.S. Food and Drug Administration, Guidance for industry: using a centralized IRB review process in multicenter clinical trials. 2006. |
3 | 공동 심사위원회 운영 가이드라인. 식품의약품안전청, 2010. |
4 | Oh JM, Recommendation for strengthening function of institutional review board and activating centralized review system. Sookmyung Women's University, 2009. (Korean) |
5 | Lee SM, Kim SH, Kim HJ, Kim OJ, Bae KS, Park BJ. Current Status of the Joint Institutional Review Boards in Foreign Countries and Suggestion for Operating in Korea. Kor J Clin Pharmacol Ther, 2006;14(2):142-150. (Korean) |
6 | Ravina B, Deuel L, Siderowf A, Dorsey ER. Local institutional review board (IRB) review of a multicenter trial: local costs without local context. Ann Neurol, 2010;67(2):258-260. DOI ScienceOn |
7 | FERCAP web site, http://www.fercap-sidcer.org |
8 | AAHRPP web site, http://www.aahrpp.org |